Skip to content

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02576912
Acronym
THC-Preg
Enrollment
38
Registered
2015-10-15
Start date
2015-02-28
Completion date
2019-06-24
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Cannabis, Marijuana, THC, Pregnenolone, Psychotic Disorders, PREG

Brief summary

The overall purpose of this study is to examine the effect of pregnenolone (PREG) on the acute psychosis-like and cognitive effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with PREG and then assessing their responses to THC.

Interventions

Active Delta-9-THC (0.036 mg/kg) given intravenously.

A dose given sublingually.

DRUGPlacebo

A placebo dose given sublingually.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Exposed to cannabis at least once in lifetime.

Exclusion criteria

* Cannabis naive * Individuals with a documented reaction/allergy to Pregnenolone

Design outcomes

Primary

MeasureTime frameDescription
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)Baseline, +110, +180, and +240 minutes after start of THC InfusionPositive, negative, and general symptoms will be assessed using the positive, negative, and general symptom subscales of the PANSS.

Secondary

MeasureTime frameDescription
Clinician Administered Dissociative Symptoms Scale (CADSS)Baseline; +15, +110, +180, and +240 minutes after start of THC infusionPerceptual alterations will be measured using the CADSS. This is a scale consisting of 19 self-reported items and 9 clinician-rated items. The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.
Visual Analog Scale (VAS)Baseline; +15, +110, +180, and +240 minutes after start of THC infusionFeeling states associated with cannabis intoxication will be measured using a self-reported visual analog scale of feeling states associated with cannabis effects (ex: high, calm, anxious). Subjects will be asked to score the perceived intensity of these feeling states at that moment on a 11mm line. These data will be captured to validate that the experiment is relevant to cannabis effects.
Psychotomimetic States Inventory (PSI)Baseline; +110, +180, and +240 minutes after start of THC infusionThe PSI is a measure of drug induced psychotomimetic states. This self-reported scale consists of 28 items rated 0 (not at all) to 3 (extremely) and will facilitate the characterization of a wide range of dissociative/hallucinatory phenomena as well as cognitive disorganization associated with the administration of THC.
Cognitive Test Battery25 minutes after start of THC infusionSeveral computer tasks will be administered in order to evaluate the effects of cannabis on verbal learning and memory, visual recognition, spatial working memory, and working memory. The battery consists of five computer tasks that lasts no longer than 20 minutes in total.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026